摘要
动脉粥样硬化 (atherosclerosis ,AS)是许多心血管疾病的主要病理基础之一 ,提高高密度脂蛋白水平具有显著的抗AS作用 ,该类药物的作用机制包括 :胆固醇酯转运蛋白 (cholesterolestertransferpro tein ,CETP)抑制剂、过氧化体增殖物激活型受体(peroxisomalproliferator activatedreceptors ,PPARs)激动剂、肝脏X活化受体 (liverX activatedreceptor,LXR)激动剂、法尼酯衍生物X受体 (farnesoidXre ceptor,FXR)拮抗剂 激动剂、脂蛋白脂酶 (lipoproteinlipase ,LPL)活化剂、烟酸类、苯妥英、卵磷脂胆固醇酰基转移酶 (lecin :cholesterolacyltransferase ,LCAT)活化剂等 ,本文回顾性地介绍了升高高密度脂蛋白的药物及其进展 ,包括临床及临床前期药物及其作用机制。
Atherosclerosis (AS) is pathologically important basis of many kinds of coronary atherosclerosis disease (CAD). It can be substantially protected by raising high-density lipoprotein (HDL).In view of mechanism, drugs for raising HDL include: cholesterol ester transfer protein inhibitors, peroxisomal proliferator-activated receptor agonists, liver X-activated receptor agonists, farnesoid X receptor antagonists or agonists, lipoprotein lipase activators, niacin, and phenytoin and lecin : cholesterol acyltransferase activators, etc. This review aimed to the progress of drugs for regulating high-density lipoprotein and their mechanism, in view of clinical and preclinical aspects.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2004年第8期841-844,共4页
Chinese Journal of Clinical Pharmacology and Therapeutics
关键词
高密度脂蛋白
动脉粥样硬化
心血管疾病
载脂蛋白
胆固醇酯转运蛋白
过氧化体增殖物激活型受体
脂蛋白脂酶
high-density lipoprotein(HDL)
atherosclerosis(AS)
coronary atherosclerosis disease(CAD)
apolipoprotein
cholesterol ester transfer protein(CETP)
peroxisomal proliferator-activated receptor(PPAR)
lipoprotein lipase(LPL)9129
